Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC
Valerie Nelson, Jacqueline Ziehr, Mark Agulnik, Melissa JohnsonRobert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USAAbstract: The discovery of epidermal growth-factor receptor (EGFR)-activating mutations and the introduction of oral EGFR tyrosine kinase inhibitors (...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2013-03-01
|
| Series: | OncoTargets and Therapy |
| Online Access: | http://www.dovepress.com/afatinib-emerging-next-generation-tyrosine-kinase-inhibitor-for-nsclc-a12369 |